Ultragenyx Pharmaceutical Inc (RARE): Next-Year EPS Estimate 84.40%
As of 2026-06-04, Ultragenyx Pharmaceutical Inc (RARE) has a next-year EPS growth estimate of 84.40%.
On 2026-05-21, analyst consensus for RARE's next-year EPS growth shifted from 84.69% to 84.40% — a negative change of 0.29 percentage points. The revised estimate has been sustained across 11 subsequent trading sessions. Current-year growth is projected at 23.11%.
Current Snapshot
- Sector
- Healthcare
- Industry
- Biotechnology
- EPS growth next year
- 84.40%
- EPS growth this year
- 23.11%
- EPS next quarter (est)
- -$1.22
- Last price
- $23.31
EPS Revision History
| Date | EPS Next Y | EPS This Y | Next Q (est) | Price |
|---|---|---|---|---|
| 2026-06-04 | 84.40% | 23.11% | -$1.22 | $23.31 |
| 2026-06-03 | 84.40% | 23.11% | -$1.22 | $22.41 |
| 2026-06-02 | 84.40% | 23.11% | -$1.22 | $21.78 |
| 2026-06-01 | 84.40% | 23.11% | -$1.22 | $22.85 |
| 2026-05-31 | 84.40% | 23.11% | -$1.22 | $23.94 |
| 2026-05-28 | 84.40% | 23.11% | -$1.22 | $23.26 |
| 2026-05-27 | 84.40% | 23.11% | -$1.22 | $23.39 |
| 2026-05-26 | 84.40% | 23.11% | -$1.22 | $23.14 |
| 2026-05-25 | 84.40% | 23.11% | -$1.22 | $23.39 |
| 2026-05-24 | 84.40% | 23.11% | -$1.22 | $23.39 |
| 2026-05-21 | 84.40% | 23.11% | -$1.22 | $23.71 |
| 2026-05-20 | 84.69% | 22.78% | -$1.22 | $23.37 |
| 2026-05-19 | 85.10% | 22.68% | -$1.23 | $22.45 |
| 2026-05-18 | 85.10% | 22.68% | -$1.23 | $24.19 |
| 2026-05-17 | 85.10% | 22.68% | -$1.23 | $25.00 |
| 2026-05-14 | 85.10% | 22.68% | -$1.23 | $25.80 |
| 2026-05-13 | 85.10% | 22.68% | -$1.23 | $26.57 |
| 2026-05-12 | 85.10% | 22.68% | -$1.23 | $26.84 |
| 2026-05-11 | 85.10% | 22.68% | -$1.23 | $26.30 |
| 2026-05-10 | 85.54% | 23.03% | -$1.24 | $26.12 |
| 2026-05-07 | 86.23% | 22.66% | -$1.23 | $26.13 |
| 2026-05-06 | 86.16% | 23.06% | -$1.23 | $25.93 |
| 2026-05-05 | 87.35% | 25.39% | -$1.50 | $25.01 |
| 2026-05-04 | 87.35% | 25.39% | -$1.50 | $24.81 |
| 2026-05-03 | 87.35% | 25.39% | -$1.50 | $24.77 |
| 2026-04-30 | 87.35% | 25.39% | -$1.50 | $24.69 |
| 2026-04-29 | 87.35% | 25.39% | -$1.50 | $24.18 |
| 2026-04-28 | 87.35% | 25.39% | -$1.50 | $24.53 |
| 2026-04-27 | 86.16% | 24.24% | -$1.49 | $23.99 |
| 2026-04-26 | 86.16% | 24.24% | -$1.49 | $24.10 |
Recent News
Screen Performance
Aggregate stats across all 1761 tickers our top-EPS-revision screen has flagged over the past 64 days.
- Median return since detection
- +5.1%
- % of tickers in the green
- 62%
- Median return on winners
- +17.5%
- Large revisions captured
- 746
Past detection performance reflects the price change between when a ticker first entered our screen and the most recent observation. Not a forward-looking forecast.
Frequently Asked Questions
What is Ultragenyx Pharmaceutical Inc's next-year EPS growth estimate?▾
As of 2026-06-04, Ultragenyx Pharmaceutical Inc (RARE) has a next-year EPS growth estimate of 84.40%, based on analyst consensus.
When was the latest EPS estimate revision for RARE?▾
The most recent revision occurred on 2026-05-21, when analysts adjusted the next-year EPS growth estimate from 84.69% to 84.40%.
What sector and industry does Ultragenyx Pharmaceutical Inc belong to?▾
Ultragenyx Pharmaceutical Inc operates in the Healthcare sector, specifically the Biotechnology industry.
How often is this EPS estimate data updated?▾
EPS revision data is refreshed daily from analyst consensus estimates. RARE appears on this page because it was flagged by our daily top-EPS-revision-performer screen.
EPS revision data sourced from analyst consensus estimates, refreshed daily. Ultragenyx Pharmaceutical Inc (RARE) appears here because it was detected by our daily top-EPS-revision-performer screen.
← All reports